Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

What Is Known about the Clinical and Economic Burden of Refractory Chronic Lymphocytic Leukemia in Clinical Practice: A Review of the Literature.

Gwilym J Thompson, MA, PhD, Vincent Lévy, MD, PhD, Krista Payne, MSc, Radek Wasiak, PhD, Yvonne Lis, PhD

Blood (2009) 114 (22): 4549.

https://doi.org/10.1182/blood.V114.22.4549.4549

Published: 2009

Journal Articles

Consolidation Therapy with Subcutaneous Alemtuzumab Following Induction Treatment with Oral FC (Fludarabine and Cyclophosphamide) in Previously Untreated Patients Aged 65-70 Years with Advanced Stage Chronic Lymphocytic Leukemia (CLL): A Phase II Trial of the FCGCLL/MW.

Alain Delmer, MD, Stéphane Leprêtre, MD, Bruno Cazin, MD, Pierre Feugier, MD, PhD, Olivier Tournilhac, MD, PhD, Michel Leporrier, MD, Brigitte Dreyfus, MD, Béatrice Mahé, MD, Catherine Thieblemont, MD, PhD, Marine Divine, MD, Vincent Lévy, MD, PhD, Véronique Leblond, MD, Florence Cymbalista, MD, PhD, Rémy Letestu, MD, PhD

Blood (2006) 108 (11): 2831.

https://doi.org/10.1182/blood.V108.11.2831.2831

Published: 2006

Journal Articles

Long-term outcome of hepatitis C infection after bone marrow transplantation

Régis Peffault de Latour, Vincent Lévy, Tarik Asselah, Patrick Marcellin, Catherine Scieux, Lionel Adès, Richard Traineau, Agnès Devergie, Patricia Ribaud, Hélène Espérou, Eliane Gluckman, Dominique Valla, Gérard Socié

Blood (2004) 103 (5): 1618–1624.

https://doi.org/10.1182/blood-2003-06-2145

Published: 2004

Journal Articles

Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease

Véronique Leblond, Vincent Lévy, Frédéric Maloisel, Bruno Cazin, Jean-Paul Fermand, Jean-Luc Harousseau, Liliane Remenieras, Raphaël Porcher, Martine Gardembas, Gérald Marit, Eric Deconinck, Bernard Desablens, François Guilhot, Guilaine Philippe, Aspasia Stamatoullas, Odile Guibon

Blood (2001) 98 (9): 2640–2644.

https://doi.org/10.1182/blood.V98.9.2640

Published: 2001

Journal Articles

Alternate designs for conduct and analysis of phase I cancer trials

Vincent Lévy, Sarah Zohar, Raphaël Porcher, Sylvie Chevret

Blood (2001) 98 (4): 1275.

https://doi.org/10.1182/blood.V98.4.1275

Published: 2001

NARROW

What Is Known about the Clinical and Economic Burden of Refractory Chronic Lymphocytic Leukemia in Clinical Practice: A Review of the Literature.

Consolidation Therapy with Subcutaneous Alemtuzumab Following Induction Treatment with Oral FC (Fludarabine and Cyclophosphamide) in Previously Untreated Patients Aged 65-70 Years with Advanced Stage Chronic Lymphocytic Leukemia (CLL): A Phase II Trial of the FCGCLL/MW.

Long-term outcome of hepatitis C infection after bone marrow transplantation

Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease

Alternate designs for conduct and analysis of phase I cancer trials

Email alerts

ASH Publications

American Society of Hematology

What Is Known about the Clinical and Economic Burden of Refractory Chronic Lymphocytic Leukemia in Clinical Practice: A Review of the Literature.

Consolidation Therapy with Subcutaneous Alemtuzumab Following Induction Treatment with Oral FC (Fludarabine and Cyclophosphamide) in Previously Untreated Patients Aged 65-70 Years with Advanced Stage Chronic Lymphocytic Leukemia (CLL): A Phase II Trial of the FCGCLL/MW.

Long-term outcome of hepatitis C infection after bone marrow transplantation

Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease

Alternate designs for conduct and analysis of phase I cancer trials

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only